Using our rapid antibody discovery platform, we engineered a novel human anti-TIM-4 antibody that effectively inhibits phagocytosis and synergizes with anti-PD-1 inhibitors to block tumor progression in a syngeneic mouse model of colon cancer. Here, TIMD4 is linked to neoplasm.